Back to top
more

Stryker (SYK)

(Real Time Quote from BATS)

$377.76 USD

377.76
399,466

+1.39 (0.37%)

Updated Aug 8, 2025 02:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (153 out of 244)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Luminex (LMNX) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research

Luminex's (LMNX) fourth-quarter earnings benefit from higher revenues and solid performance across System Sales, Service and Other Revenues. However, gross margin contraction remains a woe.

Zacks Equity Research

DaVita (DVA) Earnings Beat Estimates in Q4, Revenues Miss

by Zacks Equity Research

DaVita (DVA) gains from dialysis services in the United States in Q4.

Zacks Equity Research

Here's Why You Should Add Hill-Rom to Your Portfolio Now

by Zacks Equity Research

Investor confidence is at a high, thanks to Hill-Rom (HRC) solid prospects.

Zacks Equity Research

STERIS (STE) Surpasses Q3 Earnings Estimates, Ups FY20 View

by Zacks Equity Research

STERIS' (STE) third-quarter fiscal 2020 results reflect strong segmental performances.

Zacks Equity Research

Myriad Genetics (MYGN) Misses Q2 Earnings & Revenue Estimates

by Zacks Equity Research

Myriad Genetics (MYGN) reports decline in Hereditary Cancer, GeneSight, Vectra and Prenatal revenues in Q2.

Zacks Equity Research

Omnicell (OMCL) Lags Q4 Earnings Estimates, Beats on Revenues

by Zacks Equity Research

Omnicell (OMCL) fourth-quarter 2019 results reflect strong segmental performances.

Zacks Equity Research

Pacific Biosciences (PACB) Reports Break-Even Earnings in Q4

by Zacks Equity Research

Pacific Biosciences (PACB) expects softness in first-quarter consumable sales.

Zacks Equity Research

Is Stryker (SYK) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (SYK) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

ResMed (RMD) Rides on New Product Portfolio, SaaS Growth

by Zacks Equity Research

Within SaaS, ResMed (RMD) consistently gains momentum from the Brightree service portfolio and derives synergies from the accretive MatrixCare buyout.

Zacks Equity Research

Surmodics (SRDX) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Surmodics' (SRDX) fiscal first-quarter earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.

Zacks Equity Research

Cardinal Health (CAH) Q2 Earnings & Revenues Top Estimates

by Zacks Equity Research

Cardinal Health (CAH) fiscal second-quarter results benefit revenue growth and strong segmental performance. However, contraction in gross margin remains a concern.

Zacks Equity Research

Becton, Dickinson (BDX) Q1 Earnings Beat, Revenues Rise Y/Y

by Zacks Equity Research

Becton, Dickinson (BDX) sees softness in BD Medical unit, slashes FY20 view.

Zacks Equity Research

ABIOMED (ABMD) Earnings Beat Estimates in Q3, Revenues Miss

by Zacks Equity Research

Flagship Impella drives ABIOMED's (ABMD) fiscal third-quarter results; FY20 revenue guidance slashed.

Zacks Equity Research

Cardiovascular Systems (CSII) Loss Wider Than Estimates in Q2

by Zacks Equity Research

We are upbeat about Cardiovascular Systems' (CSII) year-over-year uptick in global Coronary and peripheral device revenues during Q2.

Zacks Equity Research

ResMed (RMD) Stock Hits New 52-Week High: What's Driving It?

by Zacks Equity Research

ResMed (RMD) is optimistic about maintaining growth momentum on several recent developments.

Zacks Equity Research

Haemonetics (HAE) Q3 Earnings & Revenues Beat, Margins Expand

by Zacks Equity Research

Haemonetics (HAE) fiscal third-quarter 2020 results reflect strong performances in Plasma and Hospital segments.

Zacks Equity Research

Boston Scientific (BSX) Q4 Earnings Beat, Margins Decline

by Zacks Equity Research

Boston Scientific (BSX) is steadily investing in new technologies as well as the global markets, reflecting its uptick in sales across most geographies in Q4.

Zacks Equity Research

Here's Why You Should Retain IDEXX Laboratories Stock Now

by Zacks Equity Research

Investor confidence remains high in IDEXX (IDXX) stock, thanks to solid prospects.

Zacks Equity Research

Medical Products Stock Feb 6 Earnings Roster: BDX, CAH & More

by Zacks Equity Research

Despite the ongoing US-China trade war, increased focus on innovation is likely to have driven performance of medical products players' quarterly performance.

Zacks Equity Research

QIAGEN (QGEN) Q4 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

QIAGEN (QGEN) registered revenue growth across majority of its geographies and each of its operating segments in Q4

Zacks Equity Research

Cerner (CERN) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research

Cerner (CERN) fourth-quarter results benefit from higher revenues, gains in Licensed software, Technology resale, Professional and Managed services units, and international revenue growth.

Zacks Equity Research

Zimmer Biomet (ZBH) Q4 Earnings Top Estimates, Margins Grow

by Zacks Equity Research

Zimmer Biomet (ZBH) benefits from strong sales growth across all geographies as well as segmental strengths at CER.

Zacks Equity Research

Phibro (PAHC) Q2 Earnings Top Estimates, Revenues Fall Y/Y

by Zacks Equity Research

Phibro (PAHC) witnessed revenue decline in two of its core segments and contraction in operating margin in Q2.

Zacks Equity Research

McKesson (MCK) Q3 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

McKesson's (MCK) fiscal third-quarter results gain from higher revenues and solid show by U.S. Pharmaceutical and Specialty Solutions, Medical-Surgical Solutions and Other segments.

Zacks Equity Research

Stryker (SYK) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Stryker's (SYK) fourth-quarter earnings gain from higher revenues, solid segmental performance and strong organic growth across businesses benefit.